Brief: Neurotech International Receives HREC Approval For Phase I/Ii Clinical Trial In Rett Syndrome
10/07/2023 02:40
July 10 (Reuters) - Neurotech International Ltd
NTI.AX :
* NEUROTECH RECEIVES HREC APPROVAL FOR PHASE I/II CLINICAL
TRIAL
IN RETT SYNDROME
Source text for Eikon: ID:nASX4ygk03
Further company coverage: NTI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt